1. Home
  2. SMMT

SMMT

Summit Therapeutics Inc.

Logo Summit Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 2:30pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Founded: 2003 Country:
United States
United States
Employees: N/A City: MENLO PARK
Market Cap: 2.5B IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 2.3M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.01 EPS Growth: N/A
52 Week Low/High: $1.30 - $5.22 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Summit Therapeutics Inc. (SMMT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Zanganeh Mahkam SMMT Chief Executive Officer Mar 26 '24 Buy $3.72 26,000 $96,720.00 520,814 SEC Form 4